Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Jul 18;137(3):e40-e61.
doi: 10.1161/CIRCRESAHA.124.325093. Epub 2025 May 15.

Rpl13a snoRNAs U34 and U35a: New Targets for Sickle Cell Disease Complications

Waseem Chauhan  1 , Sudharshan Sj  1 , Shirin Ferdowsi  1 , Sweta Kafle  1 , Rahima Zennadi  1
Affiliations

Rpl13a snoRNAs U34 and U35a: New Targets for Sickle Cell Disease Complications

Waseem Chauhan et al. Circ Res. .

Erratum in

Abstract

Background: In sickle cell disease (SCD), erythrocyte reactive oxygen species (ROS) production and oxidative stress play a critical role in vaso-occlusion, a hallmark of SCD. Small noncoding nucleolar RNAs (snoRNAs) of the Rpl13a locus have been described as regulators of ROS levels. However, whether Rpl13a snoRNAs are present in sickle red blood cells (RBCs) and regulate ROS levels and whether they contribute to SCD pathophysiology remain unknown.

Methods: To determine whether sickle RBC ROS levels are associated with Rpl13a snoRNA levels and identify the mechanism by which they regulate ROS and snoRNAs' effects on SCD hemodynamics, we used human RBCs, Rpl13a snoRNA knockout sickle mice, K562 U32a, U33, U34, U35a, and the control U25 knockout mutants generated by CRISPR-Cas9 (Clustered Regularly Interspaced Short Palindromic Repeats/Cas9 protein)-targeted genome editing, and genetic targeting with antisense oligonucleotides.

Results: Excessive ROS production in sickle RBCs of patients with SCD is associated with high Rpl13a snoRNAs U32a, U33, U34, and U35a levels. U32a, U34, and U35a regulate ROS and hydrogen peroxide levels in sickle erythroid populations by modulating peroxidase activity. This was due to U32a- and U34-guided 2'-O-methylation on Prdx2 (peroxiredoxin 2) messenger RNA, a modification conveyed by fibrillarin during erythropoiesis, subsequently reducing Prdx2 expression and activity. The snoRNA U35a impaired Prdx2 expression/activity but independently of Prdx2 messenger RNA 2'-O-methylation. Excess sickle RBC ROS increased in turn Rpl13a snoRNAs levels. In vivo targeting combinations of U34+U35a and U32a+U34+U35a in sickle mice with antisense oligonucleotide blunted RBC ROS generation, improved erythropoiesis and anemia, alleviated leukocytosis and endothelial damage, diminished cell adhesion in inflamed vessels and vaso-occlusion, restored blood flow, and reduced animal mortality.

Conclusions: Rpl13a snoRNAs U34 and U35a specifically increase ROS levels, which, in turn, regulate snoRNA expression, in sickle erythroid cells, modulating Prdx2 expression/activity, subsequently impairing hemodynamics. Targeted U34+U35a with antisense oligonucleotide may represent a novel and safe therapy to ameliorate erythropoiesis and downstream events in SCD.

Keywords: RNA, small nucleolar; anemia, sickle cell; antioxidants; endothelium, vascular; reactive oxygen species.

PubMed Disclaimer

Conflict of interest statement

R. Zennadi is listed as an inventor on patent US20240279657A1, titled "Compositions and Methods for the Prevention and Treatment of Hemoglobinopathies," which is related to the subject matter of this publication.

Similar articles

See all similar articles

References

    1. Aslan M, Thornley-Brown D, Freeman BA. Reactive species in sickle cell disease. Annals of the New York Academy of Sciences. 2000;899:375–391. - PubMed
    1. George A, Pushkaran S, Konstantinidis DG, Koochaki S, Malik P, Mohandas N, Zheng Y, Joiner CH, Kalfa TA. Erythrocyte NADPH oxidase activity modulated by Rac GTPases, PKC, and plasma cytokines contributes to oxidative stress in sickle cell disease. Blood. 2013;121:2099–2107. doi: 10.1182/blood-2012-07-441188 - DOI - PMC - PubMed
    1. George A, Pushkaran S, Li L, An X, Zheng Y, Mohandas N, Joiner CH, Kalfa TA. Altered phosphorylation of cytoskeleton proteins in sickle red blood cells: the role of protein kinase C, Rac GTPases, and reactive oxygen species. Blood Cells Mol Dis. 2010;45:41–45. doi: 10.1016/j.bcmd.2010.02.006 - DOI - PMC - PubMed
    1. Jagadeeswaran R, Vazquez BA, Thiruppathi M, Ganesh BB, Ibanez V, Cui S, Engel JD, Diamond AM, Molokie RE, DeSimone J, et al. Pharmacological inhibition of LSD1 and mTOR reduces mitochondrial retention and associated ROS levels in the red blood cells of sickle cell disease. Experimental hematology. 2017;50:46–52. doi: 10.1016/j.exphem.2017.02.003 - DOI - PMC - PubMed
    1. Nader E, Grau M, Fort R, Collins B, Cannas G, Gauthier A, Walpurgis K, Martin C, Bloch W, Poutrel S, et al. Hydroxyurea therapy modulates sickle cell anemia red blood cell physiology: Impact on RBC deformability, oxidative stress, nitrite levels and nitric oxide synthase signalling pathway. Nitric oxide : biology and chemistry / official journal of the Nitric Oxide Society. 2018;81:28–35. doi: 10.1016/j.niox.2018.10.003 - DOI - PubMed

MeSH terms